EDIT (Editas Medicine) FCF Margin %: -817.84% (As of Mar. 2026)


EDIT Editas Medicine Inc EDIT
51 GF Score
Price $2.74
GF Value $1.92
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Editas Medicine FCF Margin %?

Editas Medicine EDIT -2.14% 51 FCF Margin % is -817.84% as of Mar. 2026. GuruFocus rates EDIT with a GF Score™ of 51/100 and a GF Value™ of $1.92 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 960 Biotechnology companies, Editas Medicine ranks worse than 67.5% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Editas Medicine's Free Cash Flow for the three months ended in Mar. 2026 was $-23.15 Mil. Editas Medicine's Revenue for the three months ended in Mar. 2026 was $2.83 Mil. Therefore, Editas Medicine's FCF Margin % for the quarter that ended in Mar. 2026 was -817.84%.

As of today, Editas Medicine's current FCF Yield % is -33.55%.

The historical rank and industry rank for Editas Medicine's FCF Margin % or its related term are showing as below:

EDIT' s FCF Margin % Range Over the Past 10 Years
Min: -920.59   Med: -318.71   Max: -83.6
Current: -364.63

During the past 13 years, the highest FCF Margin % of Editas Medicine was -83.60%. The lowest was -920.59%. And the median was -318.71%.

EDIT's FCF Margin % is ranked worse than
67.5% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs EDIT: -364.63

Editas Medicine FCF Margin % Related Terms

Editas Medicine FCF Margin % Historical Data

* Premium members only.

The historical data trend for Editas Medicine's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Editas Medicine FCF Margin % Chart

Editas Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -672.49 -920.59 -175.23 -678.07 -409.30

Editas Medicine Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,028.62 -1,403.35 -414.64 -147.31 -817.84

EDIT vs PRTA, XOMA, FDMT: FCF Margin % Comparison

For the Biotechnology subindustry, Editas Medicine's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Editas Medicine FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Editas Medicine's FCF Margin % falls into.


EDIT
51GF Score
Editas Medicine Inc EDIT
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Editas Medicine FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Editas Medicine's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-165.848/40.52
=-409.30 %

Editas Medicine's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-23.153/2.831
=-817.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -817.84% mean?
Editas Medicine (EDIT) has a FCF Margin % of -817.84% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #648 out of 960 companies in the Biotechnology industry, placing it in the top 67.5%.
Is Editas Medicine's FCF Margin % too high?
Editas Medicine's current FCF Margin % is -817.84%. Based on the distribution chart, Editas Medicine ranks #648 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's FCF Margin % compare to PRTA and XOMA?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #648 out of 960 companies for FCF Margin %. This places Editas Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Editas Medicine and its competitors. Editas Medicine's current FCF Margin % is -817.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.92, compared to a current price of $2.74 — trading 42.7% above its estimated fair value. The current FCF Margin % is -817.84%. Editas Medicine's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Editas Medicine (EDIT), the current FCF Margin % is -817.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $2.74 is trading 42.7% above its estimated GF Value™ of $1.92. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

  • FCF Margin %: -817.84%
  • GF Value™: $1.92 vs. price of $2.74 (42.7% above fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges 0IFK:UK8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
51GF Score

Get the complete analysis for EDIT

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price
$1.92
GF Value